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Context. Chronic or refractory breathlessness is common and distressing. To evaluate new treatments, outcome measures
that capture change in patients’ experience are needed.
Objectives. To explore the extent to which the numerical rating scale (NRS) worst and average, and the Chronic
Respiratory Questionnaire capture change in patients’ experience during a trial of mirtazapine for refractory breathlessness.
Methods. Convergent mixed-methods design embedded within a randomized trial comprising 1) semi-structured
qualitative interviews (considered to be the gold standard) and 2) outcome measure data collected pre- and post-intervention.
Data were integrated, exploring examples where findings agreed and disagreed. Adults with advanced cancer, chronic
obstructive pulmonary disease, interstitial lung disease, or chronic heart failure, with a modified Medical Research Council
dyspnea scale grade 3 or 4 were recruited from three U.K. sites.
Results. Data were collected for 22 participants. Eleven had a diagnosis of chronic obstructive pulmonary disease, eight
interstitial lung disease, two chronic heart failure, and one cancer. Median age was 71 (56e84) years. Sixteen participants were
men. Changes in the qualitative data were commonly captured in the NRS (worst and average) and the Chronic Respiratory
Questionnaire. The NRS worst captured change most frequently. Improvement in the emotional domain was associated with
physical changes, improved confidence, and control.
Conclusion. This study found that the NRS using the question ‘‘How bad has your breathlessness felt at its worst over
the past 24 hours?’’ captured change across multiple domains, and therefore may be an appropriate primary outcome
measure in trials in this population. Future work should confirm the construct validity of this question. J Pain Symptom
Manage 2019;58:369e381.  2019 The Authors. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative
Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Breathlessness is common and distressing in
advanced disease,1e3 resulting in anxiety, physical inac-
tivity, and a poorer quality-of-life.4e6 It is a common
reason for emergency hospital admission, and remains
a challenge to assess and treat.7 There are few effectiveAddress correspondence to: Natasha Lovell, MBChB, Cicely Sa-
unders Institute, Bessemer Road, London, SE5 9PJ, United
Kingdom. E-mail: Natasha.lovell@kcl.ac.uk
 2019 The Authors. Published by Elsevier Inc. on behalf of
American Academy of Hospice and Palliative Medicine. This is an
open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).pharmacological treatment options, with some evi-
dence for opioids, but concerns regarding side effects
and small effect sizes.8 New effective treatments are ur-
gently required, and drugs which may modify process-
ing and perception of afferent information in the
brain such as antidepressants have been proposed.9
Breathlessness is a subjective experience, derivedAccepted for publication: June 5, 2019.
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Fig. 1. Common definitions.52e55
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chological, social, and environmental factors with
evolving terminology (Fig. 1).10 It is what the patient
says it is and cannot be measured fully using physiolog-
ical variables. Although there are a variety of patient-
reported outcome measures validated for
breathlessness,11e13 there remains little consensus
about which to use and when.14 The treatment being
evaluated can be an important consideration when se-
lecting which outcome measure to use; some treat-
ments may reduce the intensity of breathlessness,
others may reduce the associated distress.
The National Cancer Research Institute Palliative
Care Breathlessness Subgroup consensus statement
(2009) recommended that breathlessness severity
should be assessed in research using a single-item
measure, but that researchers should also consider
including a measure of fatigue, mastery, emotional
state, and sleep.15 However, people living with
advanced disease and breathlessness report concerns
across the following six domains of ‘‘total breathless-
ness’’: 1) physical including function, 2) emotional
concerns, 3) social impact, 4) spiritual distress, 5)
impact of control in relation to an episode of breath-
lessness and within the wider context, and 6) context
(episodic and/or chronic).6 Therefore, when testing
new treatments it is important to capture change
across these domains. The primary outcome measure
in breathlessness trials of oxygen, benzodiazepines,
and opioids is often a single-item measure, most
commonly the numerical rating scale (NRS).8,16,17
The NRS is a 0e10 scale with a rating statement or
question, anchored by a descriptive statement at each
end.18 The NRS was originally validated against
another single-item measure (the visual analog dys-
pnea scale), and validation was based on correlation
between the two measures in patients with chronic
obstructive pulmonary disease (COPD) at rest and
following exercise.18e20 The NRS was validated with
the following statement: ‘‘Indicate how much short-
ness of breath you are having right now.’’18 However,
the statement or question which accompanies the
0e10 scale has evolved over time, and intervention
studies increasingly report an assessment of average
(NRS average) and worst (NRS worst) breathlessness
over the past 24 hours.20e31 Even across studies there
are subtle differences in the wording of the accompa-
nying statement or question. Despite no validation of
these adapted versions they are increasingly adopted
as the primary outcome in breathlessness trials.
Appendix I demonstrates the variability of rating state-
ment/questions used across a number of studies. A
comparison of studies assessing pain intensity has
identified similar discrepancies, with unidimensional
scales varying in length, period, number of response
options, and verbal descriptors.32 The reviewhighlights the importance of psychometric testing,
and suggests that consistency of wording, time frame,
and format is important.32
In addition, breathlessness trials sometimes include
a multidimensional measure as a secondary outcome,
one example of this is the Chronic Respiratory Ques-
tionnaire (CRQ). The CRQ is a broader health-
related quality-of-life questionnaire, which measures
the following four domains: dyspnea, fatigue,
emotional function, and mastery.33 The CRQ has
been validated in a series of studies spanning item
development, reproducibility, responsiveness, and vali-
dation against other questionnaires including a pa-
tient global rating score.33
To ensure better quality trials in the future, it is vital to
understand whether frequently used measures capture
change inpatients’ experienceof breathlessness. This is
particularly important for the NRS (average and worst)
where wording has evolved and changed since the orig-
inal validation. This study therefore aimed to explore
whether and to what extent three commonly used mea-
sures (NRS worst, NRS average, and CRQ) capture
change in patients’ experience during a randomized
trial of mirtazapine for refractory breathlessness.Methods
Design
Convergent mixed-methods design embedded
within a randomized trial comprising 1) semi-
structured qualitative interviews and 2) quantitative
outcome measure data collected pre- and post-
intervention. Data were collected as part of a double-
blind randomized feasibility trial of mirtazapine for
refractory breathlessness (Fig. 2). Participants were
randomized to receive 28 days of trial treatment,
either oral mirtazapine or placebo. Ethical approval
was received from the U.K. Health Research Authority
(16/LO/0091). The trial was prospectively registered
on ISRCTN 32236160 and the European Clinical Tri-
als Database (EudraCT no: 2015-004064-11), where
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occurred between August 2016 and December 2017.
The qualitative and quantitative data were collected
separately, then integrated and compared in an inter-
pretation phase. The main researcher (NL) remained
blinded during data collection and analysis. Examples
were explored where the findings from both data sets
agreed and where they disagreed.
Setting
Participants were recruited from three U.K. centers,
in South London, Nottingham, and Hull. Potential
participants were identified through inpatient clinical
teams, multidisciplinary team meetings, hospital clinic
lists, and hospital databases.
Study Participants and Sampling
Those eligible for the feasibility trial were
adults with cancer, COPD, interstitial lung diseaseFig. 2. Trial flow chart. NRS ¼ numerical rating sca(ILD), or chronic heart failure, with a modified
Medical Research Council grade 3 (‘‘I stop for
breath after walking about 100 yards or after a
few minutes on the level’’) or 4 (‘‘I am too
breathless to leave the house’’ or ‘‘I am breathless
when dressing’’), with no current diagnosis of se-
vere depression, and not currently prescribed an
antidepressant medication. For full eligibility
criteria see Appendix II.
All participants were informed of the possibility of a
qualitative interview when they provided written
informed consent for the trial. Purposive sampling was
used to achieve maximum variation based on primary
diagnosis, trial completion/non-completion, and age
(<65 years or >65 years). The sample included partici-
pants from both arms of the trial. Participants were ap-
proached by telephone or in-person. All participants
provided written informed consent before interview.le; CRQ ¼ Chronic Respiratory Questionnaire.
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Quantitative Outcome Measures. The NRS (average and
worst) and CRQ were collected as part of the feasibility
trial that took place over 35 days, with patient visit con-
tacts at baseline, days 14 and 28, and phone contacts
on days 7, 21, and 35 (Fig. 2). In the trial, participants
were randomized to receive either mirtazapine or pla-
cebo for 28 days, with a final assessment on Day 35.
The NRS was completed at baseline, days 7, 14, 21,
and 28. Two NRS rating questions were asked ‘‘How
has your breathlessness been over the last 24 hours
on average?’’ (NRS average) and ‘‘What is the worst
your breathlessness has been over the last 24 hours?’’
(NRS worst). The question was anchored with the
statement ‘‘not breathless at all’’ positioned next to
number 0, and ‘‘the worst possible breathlessness’’
next to number 10.
The CRQ was completed at baseline, days 14 and 28.
The CRQ is a 20-item questionnaire, asking about the
last two weeks, with the following four domains: dys-
pnea (their fivemost important activities and how short
of breath each activity made them feel), fatigue (four
questions), emotional function (seven questions), and
mastery (four questions). Each question is scored on a
7-point Likert scale, higher scores indicated less breath-
lessness or better quality of life. Mean scores for each
domain enable comparisons between domains.34
Qualitative Interviews. Qualitative interviews were con-
ducted at the end of the trial. Interviews were conduct-
ed in a place of the participants choosing, usually their
own home, but some were conducted in hospital. A
topic guide was developed based on the literature
and refined after feedback from patient representa-
tives and the Trial Management Group (Appendix
III). The interview schedule included questions about
whether participants had perceived a change during
the trial period, and if so, what had changed. Open
questions were used to ensure that participants were
not restricted in their answers. Interviews were digi-
tally audio recorded and transcribed verbatim. A
distress protocol was developed to minimize the risk
of potential harm. All interviews were conducted by
one researcher (NL) who has a medical background
and had completed training in in-depth interviewing.
Interviews took place in 2017.Analysis
The quantitative and qualitative data were collected
and analyzed separately, then integrated and compared
in an interpretation phase.
Quantitative Outcome Measures. Measures were
compared to derive a change score from baseline to
Day 28, a period comparable to that asked about inthe qualitative interviews. Change was assessed accord-
ing to theminimal clinically important difference guid-
ance for each questionnaire.35,36 The NRS was
considered to have changed if there was a >1-point
change,35 and the CRQ threshold was>0.5 unit change
for each domain.36
Qualitative Interviews. The qualitative interviews were
analyzed through thematic analysis37 using NVIVO,
version 10 (QSR International (UK) Ltd., Warrington).
The main researcher (NL) remained blinded during
analysis to reduce the risk of interpretation bias, and
improve confidence in the findings.38,39 Transcripts
were read and re-read, and coded inductively for themes
relating to change in experience of breathlessness dur-
ing the trial. Themes were considered within the do-
mains of ‘‘total breathlessness’’ (Fig. 3).6 Perceived
changes were categorized in terms of the extent of the
change. This was based on the language used by partic-
ipants to describe any change they had perceived, for
example, ‘‘I didn’t really feel any different’’ was coded
as no change, ‘‘the benefit that I thought I felt was quite
small’’ was coded as small change, and ‘‘it hasmade a big
difference’’ was coded as large change. To improve trust-
worthiness, the main researcher (NL) remained
blinded during data collection and analysis. Three tran-
scripts were double-coded by another researcher (SE)
who produced their own coding frame. Areas of agree-
ment and disagreement in particular relating to the de-
gree of change were discussed until consensus was
achieved. A reflexive diary was also used.
Integration. Changes in patients’ experience of
breathlessness were compared at an individual level;
that is, where change was seen in the qualitative
data, we looked for evidence of change in the quanti-
tative data and vice versa. As patient report is consid-
ered the gold standard for assessing breathlessness,
we considered the qualitative interview as gold stan-
dard in this study.40 To understand whether and to
what extent quantitative measures captured change
in patients’ experience of breathlessness, we explored
examples where findings agreed and disagreed. If
both data sets identified change or neither identified
change, this was classified as agreement. If one data
set identified change but the other did not, this was
classified as disagreement. We also considered how
change was captured across the domains of ‘‘total
breathlessness,’’ and whether there were patterns of
change across domains.Results
Qualitative and quantitative outcome measure data
were collected for 22 participants (Appendix IV).
Eleven had a diagnosis of COPD, eight ILD, two
Fig. 3. Model of total breathlessness.6
Table 1
Characteristics of Participants Based on Sampling Frame
Male Female
ILD
<65 yrs old 1
>65 yrs old 5 3 (1 did not
complete trial)
COPD
<65 yrs old 2 1
>65 yrs old 5 1
CHF
<65 yrs old




>65 yrs old 1 1
ILD ¼ interstitial lung disease; COPD ¼ chronic obstructive pulmonary dis-
ease; CHF ¼ chronic heart failure.
Vol. 58 No. 3 September 2019 373Do the NRS and CRQ Capture Change in Patients’ Experience of Breathlessnesschronic heart failure, and one lung cancer. Median
age was 71 years (range 56e84 years). Sixteen were
male. Twenty had completed the trial, whereas two
withdrew because of reported adverse effects of the
trial medication. The mean interview duration was
33 minutes (range 15e104 minutes). Eight of 264
items were missing in the quantitative data. A change
score was calculated in the NRS average and worst for
21 of 22 participants and in the CRQ for 19 of 22 par-
ticipants. The characteristics of participants based on
the pre-determined sampling frame are shown in
Table 1. The coding frame for the qualitative data is
presented in Appendix V.
Patterns of Overall Agreement Between Qualitative
and Quantitative Data
Changes in experience of breathlessness for each
participant are shown in Table 2. Changes in the qual-
itative data are categorized in terms of the extent of
the change (no change, small change, and large
change). Change in the quantitative data is presented
as a change score. An assessment of whether the
change score is clinically important was calculated us-
ing guidance for each individual questionnaire, and
also presented. In the qualitative data, 12 participants
described changes in their experience of breathless-
ness during the trial. For the NRS worst and NRS
average, there was a clinically important change in
13 and nine cases, respectively. For the CRQ, there
was a clinically important change in 16 cases. There
was agreement between the qualitative data and the
NRS worst in 18 of 21 cases, the NRS average in 16
of 21 cases, and the CRQ in 15 of 21 cases. There
was agreement for change or no change in the experi-
ence of breathlessness across all measures in 12 cases.Agreement Between Patients’ Experience and Outcome
Measures
Participants described change in experience across
all domains of ‘‘total breathlessness’’ during the trial
(Appendix VI). For some participants, changes were
wide-ranging and impacted across several domains.
One male participant with COPD described physical
changes including better breathing and sleeping,
fewer emotional concerns, improved sense of well-
being, and greater sense of control. His outcome mea-
sure data showed clinically important change in NRS
worst, and emotion, mastery, and fatigue domains of
the CRQ.
Everything was so much better. I would sleep better, so if I
sleep better that means by breathing is better when I wake
up in the morning, which it never was before. I used to
struggle to get up with the breathing . they definitely
really helped. Even, even all my friends and neighbours
have said how different I am.
Participant ID 1003
Another participant reported that his breathing was
eased by changes across emotional and spiritual do-
mains. His outcome measure data showed a clinically
important change in the CRQ emotion, and NRS
worst and average.
What’s the way to describe it, a wave of, wellbeing. Erm.
Comfort, happy with my role, erm. It’s almost like id got
an extra security blanket for, for the period, you know,
that’s how it felt to me, it was one more thing protecting
me. Easing my breathing. That’s how it felt to me. It could
be wrong, but that’s how it felt, I felt it all the way through.
Participant ID 1009
For others, the change in experience of breathless-
ness was specific to one domain. It was common for
participants to describe improvements within the
emotional domain. One male participant with COPD
Table 2
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376 Vol. 58 No. 3 September 2019Lovell et al.described how feeling calm resulted in easier breath-
ing, and his outcome measure data showed a clinically
important change in the CRQ emotion, and NRS
worst and average.
It did something and it just helped me calm down a lot
quicker than I normally would. I can calm down a lot
quicker, so I can, I can breathe a lot easier. It helped me-
something to me it just helped me relax so much and
now I don- I don’t panic anymore, you know.
Participant ID 1014
A female participant with clinically important
changes in the NRS worst, CRQ emotion, and mastery
domains described fewer episodes of panic and being
able to cope better.
I seem as though I can cope better with it now as I say, you
know, the panic, erm.
Participant ID 1015
Some participants described no change in their
experience of breathlessness. This was also commonly
captured in the quantitative outcome measures, and
can be seen in the following examples. Both of these
participants had no clinically important change in
CRQ domains, or in NRS worst and average.
Perhaps find it that little bit easier to breathe. But unfortu-
nately, it didn’t happen for me.
Participant ID 1007
I just really didn’t feel as though it made any difference
Participant ID 1020Patterns of Change Across Domains
Where changes in experience were described, par-
ticipants sometimes proposed a pattern of change,
where a change in one domain was associated with a
change in another. For some, improvements within
the emotional domain were associated with improve-
ments physically. The following two participants
described feeling calmer and less frightened, and
therefore being able to do more physically. Their
outcome measure data showed clinically important
changes in NRS worst, CRQ emotion, mastery, and
fatigue.
Erm, I felt calmer. I felt as though I could do more, erm, er,
I cou- yeah I could do more, because me breathing, obvi-
ously I’d settled that bit, yeah.
Participant ID 1015
It used to frighten me to get up because I thought, I’m not
going to make it to the kitchen with the breathing, before I
get (11.48), but now I can get up, go ahead and put the
kettle on, make myself a cup of tea and I’m okay. Yeah,
it’s so, I-I-I am really glad that that I’ve done it.
Participant ID 1003
Vol. 58 No. 3 September 2019 377Do the NRS and CRQ Capture Change in Patients’ Experience of BreathlessnessFor some, a change in breathing led to improved
confidence and a sense of feeling more in control.
This increased confidence enabled participants to
try to do more, a situation they might not have at-
tempted in the past. This male participant with ILD
described feeling more in control and therefore be-
ing able to do more. His outcome measure data
showed a clinically important change in his CRQ
mastery.
It didn’t change my feelings, but, my breathing improved.
Erm, stamina-wise and control-wise. And kind of, control-
wise was that I, I didn’t get out of breath as easy, I could
do a bit more- not vast amounts, erm, but the breathing
certainly was more comfortable.
Participant ID 1017
Another female participant with COPD described
attempting to do things which she had previously
avoided because she now felt she could do it, and
was prepared to do it. Her outcome measure data
showed a clinically important change in CRQ emotion
and mastery, as well as in the NRS worst.
Well, I could do it, I could do it, and I was prepared to do
it, but normally I just wouldn’t dare to attempt doing it,
cause I know how it would end up, yeah.
Participant ID 1015Disagreement Between Patients’ Experience and
Outcome Measures
Sometimes, a perceived change in patients’ experi-
ence of breathlessness was not captured by the quanti-
tative outcome measures. One male participant with
ILD described a slow gradual change in his breathing
which he did not notice until finishing the trial and
stopping the trial medication. Although there was no
change in NRS worst scores, a clinically important
change was captured in the NRS average and CRQ
mastery or dyspnea.
Well I didn’t recognise it at the time, but it did actually
erm, improve my breathing. But, it was a noticeable
improvement. When I came off the drug.
Participant ID 1017
Another participant perceived no change during
the trial period, but his quantitative data suggested a
clinically important change in NRS worst and CRQ.
This participant described some difficulties
completing scale-based outcome measures.
It was difficult to number, and whether, if I was getting
any better or worse, it was difficult then to compare the
last reading to this reading.
Participant ID 1005Discussion
This study found that three commonly used mea-
sures (NRS average, NRS worst, and CRQ) captured
the changes that participants reported in their qualita-
tive experience. Agreement was highest with the NRS
worst, which appeared to capture changes across mul-
tiple domains using the question ‘‘How bad has your
breathlessness felt at its worst over the past 24 hours?’’
We know that patients’ describe concerns relating to
breathlessness across multiple domains,6 and there-
fore when testing new treatments, it is important to
capture change across these domains.
In this mixed-methods study, the NRS average (us-
ing the question ‘‘How bad has your breathlessness
felt on average over the past 24 hours?’’) appeared
to capture physical changes consistently, and partici-
pants with a clinically important change commonly
described easier breathing and improved physical ac-
tivity. In comparison, the NRS worst (using the ques-
tion ‘‘How bad has your breathlessness felt at its
worst over the past 24 hours?’’) appeared to capture
changes more extensively across multiple domains
including physical, emotional, spiritual, social, and
control. It is therefore possible that the NRS worst is
measuring more than one construct.
These findings suggest that it is important to
consider how the statement/question used to accom-
pany the NRS impacts on what is being measured.
The NRS was originally validated with the statement
‘‘Indicate how much shortness of breath you are hav-
ing right now.’’18 The accompanying statement/ques-
tion has evolved over time with studies increasingly
reporting an assessment of average (NRS average)
and worst (NRS worst) breathlessness over the past
24 hours (Appendix I).20e31,41,42 Even the wording
used to describe ‘‘worst breathlessness’’ varies, with
one study asking participants ‘‘What is the worst your
breathlessness has been over the last 24 hours?’’ and
another using the statement ‘‘Indicate how much
shortness of breath you are having at worst at rest
over the last 24 hours.’’20,23 Appendix I demonstrates
the variability in breathlessness studies of accompa-
nying rating statement/question, none of which to
our knowledge have been formally validated. This is
an important area for future research, as the accompa-
nying statement/question potentially changes what is
being measured.
It is interesting that there is an example in our data
where a participant has reported a higher score for the
NRS average than the NRS worst (Participant ID 1003,
Day 28). This is in keeping with the peak-end rule
where evaluation of an episode is determined by the
most distressing and final moments of the experi-
ence.43 The peak-end rule has previously been demon-
strated in induced breathlessness, with recalled
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lessness.44 More recently, a study investigated the rele-
vance of the peak-end rule when assessing
breathlessness using ‘‘NRS now,’’ ‘‘NRS average,’’ and
‘‘NRS worst.’’ The study demonstrated fallibility of
the ‘‘NRS average,’’ which was affected by current
breathlessness.21 This strengthens the argument that
the ‘‘NRS worst’’ may be more appropriate than the
‘‘NRS average’’ as an outcome measure in breathless-
ness trials.
In this mixed-methods study, change in patients’
experience in the qualitative data was captured in
at least one domain of the CRQ for 15 participants.
When a change was perceived in the qualitative
data, a clinically important change score was most
commonly seen in the emotion or mastery domain
suggesting that these domains may be particularly
important as part of the experience of breathless-
ness. In comparison, change in patients’ experience
was less commonly captured in the dyspnea domain.
This study recruited people with a modified
Medical Research Council dyspnea scale grade 3 or
4, therefore those most severely affected by breath-
lessness. The dyspnea domain of the CRQ asks partic-
ipants to identify important activities, and score how
short of breath the activity has made them. It is
possible that for this group of participants, despite
an improvement in their overall experience of
breathlessness, the activities identified in the dyspnea
domain continue to result in severe shortness of
breath, and therefore the scores do not reflect a clin-
ically important change.
The qualitative data in this mixed-methods study also
offer insights into how the domains of total breathless-
ness may be linked. Participants described how im-
provements within the emotional domain were
associated with changes physically, and they were able
to do more. A similar concept of ‘‘total pain’’ was
described by Cicely Saunders in 1964 when a patient re-
ported ‘‘the pain began in my back, but now it seems
that all of me is wrong’’.45 The model shows that pain
is the sum of all domains. In our study, one participant
described how a change in one domain was associated
with changes in other domains. In his qualitative inter-
view, he said ‘‘Everything was so much better’’ (Partici-
pant ID 1003).
Mirtazapine is licensed for the treatment of depres-
sion with potential additional beneficial effects on
anxiety, both of which are common in those experi-
encing chronic breathlessness.46,47 In this study, it is
possible that by treating an underlying anxiety or
depressive disorder, mirtazapine had a beneficial ef-
fect on the emotional response to breathlessness.
However, although not powered to detect an effect,results from this feasibility trial did not find a differ-
ence when controlling for anxiety and depression us-
ing the hospital anxiety and depression scale
(personal communication Higginson et al. 2019);
however, this will be formally investigated in a full-
scale trial.
Although the NRS (average and worst) and CRQ ap-
peared to capture change in experience of breathless-
ness in this trial, it is important to consider whether a
similar effect would be seen when evaluating a treat-
ment which is not expected to impact on anxiety.
The breathing, thinking, and functioning model
described by Spathis et al. demonstrates how ineffi-
cient breathing, feelings of anxiety, and muscle decon-
ditioning are all interlinked and can perpetuate the
experience of breathlessness.48 By using this model,
you can see how an improvement in someone’s func-
tional ability (function) may lead to improved confi-
dence and less anxiety (thinking), and so a
treatment which does not target anxiety may have a
beneficial effect on it. We therefore consider that
the NRS (average and worst) and CRQ are valid mea-
sures to use in other treatment studies which do not
specifically target anxiety.
Strengths and Weaknesses
This mixed-methods study uniquely combines qual-
itative with quantitative data collected within a blinded
randomized feasibility trial. The main researcher (NL)
remained blinded during data collection and analysis,
which is unusual and strengthens confidence in the
findings by reducing the risk of bias.38,39 However,
although the qualitative data were in-depth, a single
interview may not have been sufficient to fully capture
perceived change during and after the trial.
The NRS (24 hours) and CRQ (two weeks) assess
different periods. Although patient recall is consid-
ered the gold standard for assessing breathlessness,40
research suggests that patients have difficulty remem-
bering symptom levels beyond several days,49 and
therefore a longer recall period can result in reduced
accuracy.50 In addition, even mild cognitive impair-
ment has been shown to influence patient recall of
symptom intensity.51 Participants in this study were as-
sessed for cognitive impairment during screening, but
no formal evaluation of cognitive function was per-
formed and therefore mild cognitive impairment
may have been present. The period between the trial
ending and a qualitative interview being conducted
also varied, and this may have increased the risk of
recall bias in the qualitative interviews.
A single researcher undertook all interviews
increasing the risk of interpretation bias, and some
participants had met the researcher during the trial
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a random subset of transcripts, discussion of findings
within the research team, and use of a reflexive diary.
The quantitative data were collected by designated re-
searchers and research nurses at each site, and there
may have been variability in how outcome measures
were administered between sites and individuals,
although this was minimized by training, and use of
a data collection manual.
What This Study Adds
This study provides new evidence to support choice
of primary outcome measure in clinical trials of inter-
ventions for chronic or refractory breathlessness.
Choice of measure is key, but for some measures such
as the NRS, the accompanying statement/question is
perhaps the most important consideration. Although
multiple domain measures are often considered most
appropriate tomeasure complex symptoms like breath-
lessness, lengthy questionnaires can cause an increased
burden for participants and can lead to missing data in
clinical trials and research. In comparison, the NRS is
short, self-administered, and simple to complete.
The results of this study suggest that theNRSworst us-
ing the question ‘‘How bad has your breathlessness felt
at its worst over the past 24 hours?’’ is able to capture
change in patients’ experience of breathlessness across
domains known to be important to patients.6 It may
therefore be an appropriate primary outcomemeasure
in future breathlessness trials. However, it is important
to acknowledge that validation work is first required
to understand what constructs this question is
measuring, and even whether individual constructs
can be unpicked. These results also provide options to
support the assessment and management of chronic
or refractory breathlessness in clinical practice. For cli-
nicians, where time constraints and wanting to mini-
mize the burden to patients are key challenges, the
NRS is an easily accessible outcome measure which
could be integrated into routine clinical care. However,
there may also be situations when a more detailed
assessment is required to understand which particular
domains of breathlessness are changing, and amultiple
domain measure be most appropriate.Conclusions
The changing experience of breathlessness during
this trial was usually captured by the NRS worst, NRS
average, and CRQ. Agreement was highest with the
NRS worst, using the question ‘‘How bad has your
breathlessness felt at its worst over the past 24 hours?’’
This study suggests that the NRS worst can capture
important patient-reported changes in breathlessness,
and therefore may be an appropriate measure inbreathlessness trials. Future work should confirm the
construct validity of the NRS worst using the rating
question ‘‘How bad has your breathlessness felt at its
worst over the past 24 hours?’’Disclosures and Acknowledgments
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Wording of NRS Across Studies
Manuscript Title Author/Year/Journal NRS Wording
No detail on wording in manuscript
Fan Therapy Is Effective in Relieving
Dyspnea in Patients With Terminally Ill
Cancer: A Parallel-Arm, Randomized
Controlled Trial.
Kako J, 2018, JPSM. No detail on wording in manuscript
Low-Dose Morphine for Dyspnea in
Terminally Ill Patients with Idiopathic
Interstitial Pneumonias.
Matsuda Y, 2017, Journal of Palliative
Medicine.
No detail on wording in manuscript
The Effect of Using an Electric Fan on
Dyspnea in Chinese Patients With
Terminal Cancer.
Wong SL, 2017, Am J Hosp Palliat Care. No detail on wording in manuscript
Inspiratory High Frequency Airway
Oscillation Attenuates Resistive Loaded
Dyspnea and Modulates Respiratory
Function in Young Healthy Individuals.
Morris T, 2014, PLoS One. No detail on wording in manuscript
Dyspnea scales in the assessment of
illiterate patients with chronic
obstructive pulmonary disease.
Martinez JA, 2000, Am J Med Sci. No detail on wording in manuscript
Breathlessness now
Validation of the Dyspnea Exertion Scale
of Breathlessness in People With Life-
Limiting Illness.
Sandberg J, 2018, JPSM. How is your breathlessness right now?
Verbal numerical scales are as reliable and
sensitive as visual analog scales for rating
dyspnea in young and older subjects.
Morris NR, 2007, Respir Physiol Neurobiol. How short of breath are you right now
Effect of Prophylactic Fentanyl Buccal
Tablet on Episodic Exertional Dyspnea:
A Pilot Double-Blind Randomized
Controlled Trial.
Hui D, 2017, JPSM. Dyspnea intensity now
Impact of Prophylactic Fentanyl Pectin
Nasal Spray on Exercise-Induced
Episodic Dyspnea in Cancer Patients: A
Double-Blind, Randomized Controlled
Trial.
Hui D, 2016, JPSM. Dyspnea intensity ‘‘now’’
Magnetoencephalography to investigate
central perception of exercise-induced
breathlessness in people with chronic
lung disease: a feasibility pilot.
Johnson MJ, 2015 BMJ Open. Breathlessness intensity ‘‘now,’’ at maximal
exertion, and then every minute during
recovery.
Assessment of dyspnoea in the emergency
department by numeric and visual
scales: A pilot study.
Placido R, 2015, Anaesth Crit Care Pain Med. Tell me on a scale of 0e10, what is the level
of your shortness of breath. Zero is no
shortness of breath and 10 is the worst
possible shortness of breath you can
possibly imagine.
Effects of prophylactic subcutaneous
fentanyl on exercise-induced
breakthrough dyspnea in cancer
patients: a preliminary double-blind,
randomized, controlled trial.
Hui D, 2014, JPSM. Intensity of dyspnea ‘‘now’’
High Flow Oxygen and Bilevel Positive
Airway Pressure for Persistent Dyspnea
in Patients With Advanced Cancer: A
Phase II Randomized Trial.
Hui D, 2013, JPSM. Intensity of dyspnea ‘‘now’’
Proposing a standardized method for
evaluating patient report of the intensity
of dyspnea during exercise testing in
COPD.
Hareendran A, 2012, Int J Chron Obstruct
Pulmon Dis.
Participants asked to indicate how much
shortness of breath they are having right
now
Average and worst breathlessness
Are within-person Numerical Rating Scale
(NRS) ratings of breathlessness ’on
average’ valid in advanced disease for
patients and for patients’ informal
carers?
Wade J, 2017, BMJ Open Respir Res. What is the worst your breathlessness has
been over the last 24 hours?
How has your breathlessness been over the




Manuscript Title Author/Year/Journal NRS Wording
Assessment of Breathlessness in Lung
Cancer: Psychometric Properties of the
Dyspnea-12 Questionnaire.




ability to cope with breathlessness
Practical Dyspnea Assessment:
Relationship Between the 0e10
Numerical Rating Scale and the Four-
Level Categorical Verbal Descriptor
Scale of Dyspnea Intensity.
Wysham NG, 2015, JPSM. How is your breathlessness right now?
How has your breathlessness been
over the last 24 hours, on average?
What is the worst your breathlessness
has been over the last 24 hours?
An integrated palliative and respiratory
care service for patients with advanced
disease and refractory breathlessness: a
randomised controlled trial.
Higginson IJ, 2014, The Lancet
Respiratory Medicine.
Indicate how much shortness of breath
you are having on average over the
last 24 hours?
At worst at rest over the last 24 hours?
On exertion over the last 24 hours?
A randomised controlled trial of three or
one breathing technique training
sessions for breathlessness in people
with malignant lung disease.
Johnson MJ, 2015, BMC Med. Worst breathlessness over the previous
24 hours
Average intensity of breathlessness
over the past 24 hours
Distress due to breathlessness
Coping with breathlessness
Satisfaction with care of breathlessness
Management of the respiratory distress
symptom cluster in lung cancer: a
randomised controlled feasibility trial.
Yorke J, 2015, Supportive
Care in Cancer.
Average breathlessness in
the past 24 hours
Worst breathlessness in
the past 24 hours




Ability to cope with breathlessness
Repeat dose opioids may be effective for
breathlessness in chronic heart failure if
given for long enough.
Oxberry SG, 2013, Journal of Palliative
Medicine.
Average and worst breathlessness
over the past 24 hours
Distress, satisfaction, and coping with
breathlessness
A randomised trial of high vs. low intensity
training in breathing techniques for
breathless patients with malignant lung
disease: a feasibility study.
Barton R, 2010, Lung Cancer. Perceived severity of breathlessness
(average and worst over the
past 24 hours, and ‘‘now’’)
Distress caused by breathlessness
Ability to cope with breathlessness
The effect of resistance inspiratory muscle
training in the management of
breathlessness in patients with thoracic
malignancies: a feasibility randomised
trial.
Molassiotis A, 2015, Support Care Cancer. Perceived severity of breathlessness
(average and ‘‘worst’’ over the past
24 hours, and ‘‘now’’) and distress
caused by breathlessness
Ability to cope with breathlessness
Minimally clinically important difference
in chronic breathlessness: Every little
helps.
Oxberry SG, 2012, Am Heart J. Intensity of average breathlessness
over the past 24 hours
Worst breathlessness
over the past 24 hours
Short-term opioids for breathlessness in
stable chronic heart failure: a
randomized controlled trial.
Oxberry SG, 2011, Eur J Heart Fail. Severity of average breathlessness
Worst breathlessness
over the past 24 hours
Breathlessness ‘‘now’’
Coping with breathlessness
Effect of palliative oxygen versus room air
in relief of breathlessness in patients
with refractory dyspnoea: a double-
blind, randomised controlled trial.
Abernethy AP, Lancet, 2010. Breathlessness right now
Average dyspnea in
the past 24 hours
Worst breathlessness in
the past 24 hours
Relief of dyspnea over
the previous 24 hours
Average breathlessness
Association of Descriptors of
Breathlessness With Diagnosis and Self-
Reported Severity of Breathlessness in
Patients With Advanced Chronic
Obstructive Pulmonary Disease or
Cancer.
Chowienczyk S, 2016, JPSM. How has your breathlessness
been over the last 24 hours
on average?
How distressed are you by your
breathlessness?
(Continued)
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Continued
Manuscript Title Author/Year/Journal NRS Wording
Worst breathlessness and breathlessness now
Predictors of response to corticosteroids
for dyspnea in advanced cancer
patients: a preliminary multicenter
prospective observational study.
Mori M, 2017, Support Care Cancer. Dyspnea worst
Dyspnea now
Distress due to breathlessness
Is a specialist breathlessness service more
effective and cost-effective for patients
with advanced cancer and their carers
than standard care? Findings of a
mixed-method randomised controlled
trial.
Farquhar MC, 2014, BMC Med. Patient distress due to breathlessness
The clinical and cost effectiveness of a
Breathlessness Intervention Service for
patients with advanced non-malignant
disease and their informal carers: mixed
findings of a mixed method randomised
controlled trial.
Farquhar MC, 2016, Trials. Patient distress due to breathlessness
Other
Acupuncture for Dyspnea in Lung Cancer:
Results of a Feasibility Trial.
Bauml J, 2016, Integr Cancer Ther. Dyspnea severity in the past 7 days
Morphine in the management of
dyspnoea in ALS. A pilot study.
Clemens KE, 2008, Eur J Neurol. Intensity of dyspnea
Do the trajectories of dyspnea differ in
prevalence and intensity by diagnosis at
the end of life? A consecutive cohort
study.
Currow DC, 2010, JPSM. Intensity of dyspnea
NRS ¼ numerical rating scale.
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Full eligibility criteria
Inclusion criteria:
1. Male or female aged $18 years
2. Diagnosed with cancer, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), or chronic heart
failure (New York Heart Association (NYHA) Class III or IV)
3. Breathlessness severity: modified MRC dyspnea scale grade 3 or 4
4. On optimal treatment of the underlying condition in the opinion of the identifying clinician
5. Management of the underlying condition has remained unchanged for the previous one week
6. Reversible causes of breathlessness optimally treated in the opinion of the identifying clinician
7. Expected prognosis of two months or more
8. If female and of childbearing potential agrees to use adequate contraception
9. Able to complete questionnaires and trial assessments
10. Able to provide written informed consent
Exclusion criteria:
1. Existing antidepressant use
2. Known contraindication to mirtazapine
3. Hypersensitivity to the active substance or to any of the components of the mirtazapine or placebo (e.g., lactose
intolerance)
4. Australia modified Karnofsky Performance Scale #40
5. Pregnant or breast-feeding women
6. Patients with acute cardiac events within three months of randomization (myocardial infarction, unstable angina pectoris,
or significant cardiac conduction disturbance)
7. Patients with known hepatic impairment
8. Patients with known renal impairment
9. Patients with uncontrolled blood pressure
Vol. 58 No. 3 September 2019 381.e4Do the NRS and CRQ Capture Change in Patients’ Experience of Breathlessness10. Patients with uncontrolled diabetes mellitus
11. Patients with uncontrolled seizures, epilepsy, or organic brain syndrome
12. Patients with severe depression or suicidal thoughts
13. Patients with a history of psychotic illness (schizophrenia, bipolar disorder, mania, hypomania, or other psychotic
disturbances)dix IIIAppenTopic Guide
You have recently taken part in a study called Better B. I would like to talk to you to understand your experi-
ence of taking part, what you expected, and what it was like.
If you want to stop the interview at any point let me know. You do not need to give a reason, and your clinical
care will not be affected. Everything you say will be kept confidential.
Do you have any questions before we begin?Introduction/Better-B
What did you understand about the study?
What was your experience of taking part?
Prompt: Can you tell me a bit about that?Recruitment/joining the study
How were you asked to take part in the study?
What was that like?
Prompt: Who spoke to you? What were you told? Where were you at the time?
What were your expectations?
Why did you decide to take part?
Prompt: What specifically did you want to see improved? What change were you hoping for?Trial Processes/Taking Part
What did you understand about the treatment you received?
Prompt: What did you think about taking an antidepressant medication? What do you understand about a placebo drug/
randomization?
How did you find taking the medication?
Probe: Did you have any difficulties? How did you manage with your other medications? (Dosette Box/Blister Pack/Diary as
reminder).
How did you being visited at home?
Would you have preferred to have been seen somewhere else?
How did you find it completing the questionnaires?
Probe: What did you think about the questions we asked? Do you think they were the right questions? Did they capture what is
important to you?
Would anything have made it easier to take part?
Probe: What were the downsides to taking part?Change
Tell me in what ways the drug changed how you felt?
Prompt: Did you notice any change in your breathing, sleep, appetite, drowsiness?
What did you hope would change?
For you what would be the most important change?
Were there any changes you had not expected?
381.e5 Vol. 58 No. 3 September 2019Lovell et al.Closing Section
Is there anything else that you think is important for me to know?
Is there anything that has worried you during the course of this conversation?
Is there anything else you would like to talk about?Appendix IV
Participant Demographics
Participant
ID Age, yrs Diagnosis Gender
Trial Completer/
Noncompleter
1001 84 ILD Male Completer
1002 70 COPD Male Completer
1003 68 COPD Male Completer
1004 71 COPD Male Completer
1005 76 ILD Male Completer
1006 71 HF Male Completer
1007 66 ILD Male Completer
1008 64 ILD Male Completer
1009 78 COPD Male Completer
1010 70 ILD Female Completer
1011 70 COPD Female Completer
1012 67 ILD Male Completer
1013 73 COPD Male Completer
1014 64 COPD Male Completer
1015 74 COPD Female Completer
1016 82 HF Male Non completer
1017 72 ILD Male Completer
1018 83 Cancer Female Completer
1019 74 ILD Female Non completer
1020 62 COPD Male Completer
1021 56 COPD Female Completer
1022 81 COPD Male Completer
ILD ¼ interstitial lung disease; COPD ¼ chronic obstructive pulmonary dis-
ease; HF ¼ heart failure.
Appendix V
Thematic Coding Framework
Overarching Theme Theme Subtheme Node
Change in experience
of breathlessness
Physical Relief of symptom Easier breathing
Improved appetite
Able to eat more
Improved sleeping
Able to do more More active
Able to do activities of daily living more easily
Perceived adverse effects of trial medication Feeling sick
Feeling drowsy
Emotional Sense of wellbeing Feeling more relaxed
Feeling calm
Feeling more upbeat and positive
Response to episodes of panic Able to calm down more quickly
Not feeling frightened




Able to enjoy life
Social Able to go out more Able to socialize
Able to meet other people
Feeling less isolated
Able to enjoy activities
Impact on relationships Positive impact on close relationships
Less reliant on others
Control Sense of control During episode of breathlessness
Less likely to restrict or avoid activities
Increase in confidence Able to be more independent
Less reliant on others
Appendix VI




The physical impact of breathlessness was prominent
for all participants, and many hoped to see
improvements in activity levels from taking the trial
medication.
Physical It would be nice that I would actually be able to walk down the
hill, as well as erm, you know, I, I used to be able to, I had a
problem coming up the hill, but erm, now I have a problem
walking down the hill as well. Participant ID 1010
The emotional impact of breathlessness was also
common with participants describing a repeated
cycle of breathlessness and anxiety. Some
participants reflected on whether a medication
which enabled them to feel calmer could break this
cycle.
Emotional You can get out of breath and then you can panic, cause you’re
not getting your breath and you’re not breathing through
your nose and letting it out through your mouth, you’re sort
of gasping. Participant ID 1018
The physical and emotional effects caused distress in
other aspects of participant’s lives, commonly
impacting on social and spiritual domains.
Social and Spiritual It turns you into a prisoner really, not being able to do
anything, without getting shortness of breath. Participant
ID 1013
I’ve been used to walking up mountains and, in the Lake
District and erm, the Dales and I can’t do any of that now.
And er, it really does get me down that I can’t do housework
the same, gardening, everything. Participant ID 1015
Control and context were important across all
domains. One participant described withdrawing
from social activities for fear that an episode of
breathlessness might occur. For another, the
unpredictability of breathlessness left them feeling
unable to make plans.
Context and Control Well, you, you’re maybe struggling to breathe, and then you’re
getting yourself all hot and in a bother and then that sort of
gets you churning in your stomach and then your chest
seems to close up even more, and then you start sweating
and all that type of thing, and I think, I was hoping that
taking the, the medication would calm me down and it
would be like ‘right, relax, take a breath, everything’s fine’,
and then I wouldn’t be suffering those symptoms.
Participant ID 1021
(Continued)






I can’t plan going out, cause, from day-to-day you can think,
oh we’ll go this tomorrow, then you wake up tomorrow and
you just cant do anything. So plans, you just don’t plan
anything, you go day-to-day and see how you are.
Participant ID 1013
Appendix VII. NRS Change over time. NRS ¼ numerical rating scale.
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